« Previous Next »European Journal of Cancer
Volume 41, Issue 18 , Pages 2806-2811, December 2005

Periosteal osteosarcoma – a European review of outcome

Robert J. Grimer
- The Royal Orthopaedic Hospital Oncology Service, Royal Orthopaedic Hospital, Bristol Road South, Northfield, Birmingham B31 2AP, UK
- Corresponding author. Tel.: +44 121 685 4150; fax: +44 121 685 4146.
Stefan Bielack
- The Cooperative Osteosarcoma Study Group (COSS), University Children’s Hospital, Department of Paediatric Haematology and Oncology, Muenster, Germany
Silke Flege
- The Cooperative Osteosarcoma Study Group (COSS), University Children’s Hospital, Department of Paediatric Haematology and Oncology, Muenster, Germany
Stephen R. Cannon
- Royal National Orthopaedic Hospital, London, UK
Gunnar Foleras
- The Norwegian Radium Hospital, Oslo, Norway
Ivan Andreeff
- University Hospital of Orthopaedics, Sofia, Bulgaria
Todor Sokolov
- University Hospital of Orthopaedics, Sofia, Bulgaria
Antonie Taminiau
- Leiden University Medical Centre, Leiden, Netherlands
Martin Dominkus
- University of Vienna Medical School, Vienna, Austria
Mikel San-Julian
- University of Navarra, Navarra, Spain
Yehuda Kollender
- Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel
Georg Gosheger
- University of Muenster, Muenster, Germany
from The European Musculo Skeletal Oncology Society (EMSOS)

Received 23 March 2005; received in revised form 20 April 2005; accepted 20 April 2005.

Abstract

Periosteal osteosarcoma is a rare primary malignant bone tumour. Treatment is by surgical excision, but controversy remains about the value of chemotherapy. The members of the European Musculo Skeletal Oncology Society (EMSOS) collaborated to produce a dataset of 119 patients. The predominant site for the tumour was the femur, followed by the tibia. All but 2 patients underwent surgery, with 9 requiring amputation and the others having limb salvage. A total of 81 patients had chemotherapy, of whom 50 had neoadjuvant chemotherapy. There was no standard chemotherapy regime, but all patients receiving chemotherapy were given doxorubicin combined with at least one other agent. The overall survival was 89% at 5 years and 83% at 10 years. Eight patients developed local recurrence, of whom 5 died. Survival was related to appearance of local recurrence (P<0.0001) but no other single factor. The use of chemotherapy was not shown to be a prognostic factor, but was used in two-thirds of the patients in this study.